Australia's most trusted
source of pharma news
Posted 19 March 2026 AM
After a long career in Big Pharma, seasoned licensing executive Nilesh Wadhwa has been snapped up by ASX-listed Firebrick Pharma, tasked with driving approvals and sales of its Nasodine product range.
Following an independent international search, the Melbourne-based company named Wadhwa as Head of Business Development and Licensing, a new role created to drive the number of markets where Nasodine is approved and/or sold from three countries to up to 10 countries over the next three years.

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.